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Background: Grade groups (GGs) are an important parameter for therapeutic decision
making in prostate cancer (Pca) patients. Invasive cribriform and/or intraductal carcinoma
(CR/IDC) has an independent prognostic value for disease outcome, but are not included in
the GG limiting their clinical use.
Objective: To perform a proof-of-principle study incorporating CR/IDC in the current GG.
Design, setting, and participants: All prostate biopsies of 1031 men with screen-detected Pca
between 1993 and 2000 were reviewed for the current GG (ranging from 1 to 5) and CR/IDC.
The cribriform grade (cGrade) was equal to the GG if CR/IDC was present and GG minus 1 if
not. GG1 was cGrade1 if intraductal carcinoma was absent.
Intervention: Biopsy review for GG and CR/IDC. A total of 406 patients had received radical
prostatectomy (RP), 508 radiotherapy (RT),108 surveillance, and eight hormonal therapy, and
the treatment was unknown for one patient.
Outcome measurements and statistical analysis disease-specific survival (DSS), metastasis-
free survival (MFS), and biochemical recurrence–free survival (BCRFS) after 15.1 yr (interquar-
tile range 10.9–19.7 yr) follow-up were compared using Harrell’s C-statistic.
Results and limitations: The biopsy GGs were 486 GG1, 310 GG2, 104 GG3, 64 GG4, and
67 GG5; cGrade distributions were 738 cGrade1, 102 cGrade2, 91 cGrade3, 58 cGrade4, and
42 cGrade5. The cGrade had a better discriminative value than the GG for DSS (C-index 0.79;
95% confidence interval 0.74–0.83 vs 0.76; 0.71–0.82) and MFS (0.79; 0.74–0.84 vs 0.77; 0.72–
0.82). The discriminative value for BCRFS after RP and RT was similar for both models.
Different diagnostic, such as use of sextant biopsies, and therapeutic strategies in the 1990s
are the limitations of this study.
Conclusions: The cGrade is a simple Pca grade modification with better discriminative values
for DSS and MFS than the GG, particularly impacting decision making in men with current
GG2 Pca.
Patient summary: Microscopic grading is an important factor for decision making in prostate
cancer (Pca) patients. We show that a simple grade modification better predicts Pca outcome
and might improve treatment choices.
© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.. Department of Pathology, Erasmus University Medical Centre Rotterdam,
otterdam, The Netherlands. Tel. +31 10 7043901; Fax: +31 10 7038430.
enders@erasmusmc.nl (Geert J.L.H. van Leenders).* Corresponding author
Postbus 2040, 3000CA R
E-mail address: g.vanlePlease cite this article in press as: van Leenders GJLH, et al. Improved Prostate Cancer Biopsy Grading by Incorporation of Invasive
Cribriform and Intraductal Carcinoma in the 2014 Grade Groups. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.07.051
https://doi.org/10.1016/j.eururo.2019.07.051
0302-2838/© 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.
E U R O P E A N U R O L O G Y X X X ( 2 0 1 9 ) X X X – X X X2
EURURO-8520; No. of Pages 81. Introduction
The Gleason grading system is one of the most important
parameters for clinical decision making in prostate cancer
(Pca) patients. Gleason score (GS) is entirely based on
pathological assessment of tumour growth patterns and
takes into account tumour heterogeneity. While the system
was first developed in the late 1960s, it has been modified
several times over the years and is currently based on the
2014 consensus conference of the International Society of
Urologic Pathology (ISUP) [1,2].
Although the Gleason grading system has been estab-
lished for several decades, it has a few weaknesses. Firstly, the
GS ranges between 2 and 10, which might give patients with
GS 6 a false impression to have a tumour of intermediate
grade. Secondly, the clinically important distinction between
GS 3 + 4 and GS 4 + 3 is not clearly reflected by GS 7 [3]. To
overcome these weaknesses, Pierorazio and colleagues [4]
introduced “grade groups” (GGs), which are defined as
follows: GG1 (GS  6), GG2 (GS 3 + 4 = 7), GG3 (GS 4 + 3 = 7),
GG4 (GS 8), and GG5 (GS9–10). The GGs were endorsed by the
ISUP and the World Health Organization (WHO), and should
be reported in conjunction with the GS [1,2].
In recent years, much evidence was obtained that
invasive cribriform and/or intraductal carcinoma (CR/IDC)
are pathological features with strong independent predic-
tive values for disease-specific survival (DSS), biochemical
recurrence–free survival (BCRFS), and adverse pathological
parameters at radical prostatectomy (RP) [5–10]. Patients
with biopsy GG2 Pca with presence of CR/IDC show
significantly shorter DSS and BCRFS than those without
[8,9]. On the contrary, DSS and BCRFS of biopsy GG2 Pca
patients without CR/IDC are not statistically different from
those of men with GG1 Pca [8,9]. Furthermore, patients with
biopsy GG1 Pca with concomitant intraductal carcinoma
often show aggressive features at subsequent RP with
extraprostatic expansion in up to 64% of cases [11]. Although
invasive cribriform Gleason pattern 4 and intraductal
carcinoma are strictly two separate pathological entities,
they show significant morphological overlap and often
coincide. Despite the accumulating evidence of their
additional prognostic impact, presence of CR/IDC is not
included in the current grading system. This limits their
comprehensive and simple incorporation in clinical deci-
sion models.
In the current proof-of-principle study, we investigate a
modified Pca grading model for prostate biopsies—cribri-
form grade (cGrade)—which incorporates CR/IDC in the
established GG system.
2. Patients and methods
2.1. Patient selection
We identified all 1078 men from the first screening round of
the Dutch part of the European Randomized Study of
Screening for Prostate Cancer (ERSPC), who had been
diagnosed with Pca between November 1993 and March
2000 at the Erasmus University Medical Centre, Rotterdam,Please cite this article in press as: van Leenders GJLH, et al. Improv
Cribriform and Intraductal Carcinoma in the 2014 Grade GroupsThe Netherlands [12]. The ERSPC is an ongoing multicentre
randomised screening trial that was initiated in the early
1990s to evaluate the effect of screening with prostate-
specific antigen (PSA) testing on disease-specific mortality
rates. Exclusion criteria of the present study were unavail-
ability of slides or paraffin blocks for review (n = 24) and
presence of lymph node or distant metastasis at the time of
diagnosis (n = 23), leaving 1031 patients for analysis. The
study was approved by the institutional Medical Research
Ethics Committee (MEC-2018-1614) and in concordance
with the Declaration of Helsinki.
2.2. Pathological evaluation
Three investigators (C.K., I.K., and G.v.L.), who were blinded
to patient information and outcome, revised all available
histopathological slides (n = 1031) according to the
2014 WHO/ISUP recommendations [2]. For each biopsy
core, we recorded GS, GG, presence of CR/IDC, and
percentage Gleason pattern 4 [13]. Invasive cribriform
structures were defined as both small and expansive
malignant epithelial proliferations with intercellular lumi-
na, in which the majority of tumour cells did not contact
surrounding stroma and which spanned at least half of the
glandular lumen. Intraductal carcinoma was diagnosed
according to the WHO criteria [1]. Basal cell immunohis-
tochemistry was performed to differentiate invasive cribri-
form from intraductal carcinoma in case this was not
evident by histopathological parameters alone [9]. Since
invasive cribriform and intraductal carcinoma show signif-
icant morphological overlap and both have added clinical
values, we combined both patterns into one group (CR/IDC).
The worst biopsy GG was used for statistical analyses.
2.3. Cribriform grade
The cGrade was conceived as a modification of the GG
system and was determined as follows (Supplementary Fig.
1). For Pca patients with GG2–5, the cGrade is similar to the
GG if CR/IDC is present. The cGrade is equal to the GG minus
1, if CR/IDC is absent. For men with GG1, the cGrade is 1. In
the rare case of GG1 Pca with concomitant intraductal
carcinoma, the assigned cGrade is 2.
2.4. Clinical follow-up
After diagnosis and initial treatment, patients were moni-
tored semiannually by a chart review to assess potential
progression and secondary treatments. DSS was defined as
the time from diagnosis to death attributed to Pca and was
evaluated by an independent causes of death committee
[12]. Metastasis-free survival (MFS) was defined as the time
from diagnosis to the development of distant metastasis or
censoring. Biochemical recurrence was defined as a PSA
level of 0.2 ng/ml assessed at two consecutive time points
>3 mo apart after RP or any PSA increase of >2 ng/ml higher
than the PSA nadir value after radiotherapy (RT) [14]. BCRFS
was defined as the time from RP or the start of RT to
biochemical recurrence or censoring.ed Prostate Cancer Biopsy Grading by Incorporation of Invasive
. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.07.051
Fig. 1 – Kaplan-Meier survival probabilities of Pca patients stratified for the presence or absence of CR/IDC in (A) grade group (GG) 2, (B) GG3, (C) GG4,
and (D) GG5.
CI = confidence interval; CR/IDC = invasive cribriform and/or intraductal carcinoma; DSS = disease-specific survival; Pca = prostate cancer.
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For DSS and BCRFS analyses, both GG and cGrade were
included in five categories (GG1–5 and cGrade1–5), and
percentage Gleason pattern 4 was included as a continuous
variable. Hazard ratios (HRs) for survival time were
calculated using univariable Cox proportional hazard
regression. To adjust for different treatments, we included
a stratified baseline hazard for treatment and estimated
common HR for GG and cGrade. Survival probabilities were
plotted using Kaplan-Meier curves. Discriminative ability
for grading models was quantified using Harrell’s C-index.
All statistical analyses were performed in SPSS version 24
(IBM, Chicago, IL, USA) and R version 3.2.2 (R, Vienna,Please cite this article in press as: van Leenders GJLH, et al. Improve




Our study cohort contained 1031 screen-detected Pca
patients (Table 1). Their median age at the time of diagnosis
was 67 yr (interquartile range [IQR] 62–71 yr) and the
median PSA level was 5.6 ng/ml (IQR 3.9–8.8 ng/ml). In total,
549 (53.3%) men received six biopsies, 460 (44.6%) seven
biopsies, and 22 (2.1%) eight biopsies. Four hundred and six
(39.2%) patients underwent RP, 508 (49.0%) underwent RT,d Prostate Cancer Biopsy Grading by Incorporation of Invasive
 Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.07.051
Table 1 – Patient characteristics of the study population.
GS  6 GG1
(n = 486)
GS 3 + 4 = 7 GG2
(n = 310)






Age, median (IQR) 66 (61–70) 67 (62–71) 69 (65–72) 69 (66–72) 67 (64–71)
PSA, median (IQR) 4.7 (3.5–6.9) 5.8 (4.0–9.0) 7.4 (4.7–14.9) 11.0 (6.1–17.4) 9.4 (5.3–16.3)
CR/IDC, n (%) 4 (0.8) 54 (17.4) 60 (57.7) 33 (51.6) 42 (62.7)
Radical prostatectomy, n (%) 216 (44.4) 129 (41.6) 33 (32.0) 14 (21.9) 14 (20.9)
Radiation therapy, n (%) 188 (38.7) 154 (49.7) 66 (64.1) 48 (75.0) 52 (77.6)
Active surveillance/WW, n (%) 80 (16.5) 23 (7.4) 3 (2.9) 1 (1.6) 1 (1.5)
Hormonal therapy, n (%) 2 (0.4) 3 (1.0) 2 (1.9) 1 (1.6) 0
Unknown, n (%) 0 1 (0.3) 0 0 0
CR/IDC = invasive cribriform and/or intraductal carcinoma; GG = grade group; GS = Gleason score; IQR = interquartile range; PSA = prostate-specific antigen;
WW = watchful waiting.
Table 2 – Distribution and relation of grade groups (GGs) and
cribriform grade (cGrade).
GG1 GG2 GG3 GG4 GG5 Total
cGrade1 482 256 – – – 738
cGrade2 4 54 44 – – 102
cGrade3 – – 60 31 – 91
cGrade4 – – – 33 25 58
cGrade5 – – – – 42 42
Total 486 310 104 64 67 1031
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lance, and eight (0.8%) received hormonal therapy. Primary
treatment was unknown in one (0.1%) patient. The median
follow-up of patients being alive at the last follow-up was
15.1 yr (IQR 10.9–19.7 yr).
The biopsy grade distribution was as follows: 486 Pca
cases were graded as GG1 (GS  6), 310 cases as GG2 (GS
3 + 4 = 7),104 cases as GG3 (GS 4 + 3 = 7), 64 cases as GG4 (GS
8), and 67 cases as GG5 (GS 9 or 10). A total of 566 (54.9%)
men died during follow-up, 90 (8.7%) of whom died from
Pca. Disease-specific death occurred in 2.1% (10/486) of
patients diagnosed with biopsy GG1, 6.5% (20/310) with
GG2, 22.1% (23/104) with GG3, 25.0% (16/64) with GG4, and
31.3% (21/67) with GG5 Pca.
3.2. Cribriform growth and/or intraductal carcinoma and DSS
Four (0.8%) GG1 (GS  6) Pca patients had concomitant
intraductal carcinoma of the prostate. CR/IDC was observed
in 54 (17.4%), 60 (57.7%), 33 (51.6%), and 42 (62.7%) patients
with GG2, GG3, GG4, and GG5 Pca, respectively (Fig. 1). In
multivariable analysis including the five GG categories,
biopsy CR/IDC had additional predictive values for DSS (HR
3.8; 95% confidence interval [CI] 2.3–6.3; p < 0.001) and
MFS (HR 3.7; 95% CI 2.2–6.2; p < 0.001). Adding an
interaction between GG and CR/IDC did not lead to a
significantly better model fit for DSS (p = 0.8) or MFS (p =
0.6). Of interest, DSS of men with biopsy GG2 Pca without
CR/IDC was not different from the DSS of those with GG1
Pca (HR 1.9; 95% CI 0.8–4.7; p = 0.15). While percentage
Gleason pattern 4 has also been recognised as a parameter
for clinical stratification of GG2 Pca patients, it did not have
a predictive value for DSS (HR 1.5; 95% CI 0.03–73.7; p = 0.8)
or MFS (HR 1.4; 95% CI 0.03–64.1; p = 0.9) as a continuous
variable in our cohort [1,5,15].
3.3. Cribriform grade modification
Distribution of cGrade among the 1031 patients was as
follows: 738 patients were graded as having cGrade1, 102 as
cGrade2, 91 as cGrade3, 58 as cGrade4, and 42 as cGrade5
Pca (Table 2). Incorporation of CR/IDC in the cGrade had the
most prominent effect in GG2 tumours, of which 256/310
(82.6%) were classified as cGrade1. Reclassification occurredPlease cite this article in press as: van Leenders GJLH, et al. Improv
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GG4, and GG5 Pca cases, respectively. Only four out of
486 patients with GG1 Pca (0.8%) were upgraded to cGG2
due to the presence of intraductal carcinoma.
3.4. DSS and MFS
Both grading systems were strongly associated with clinical
outcome (Table 3). The discriminative value of the cGrade
(C-index 0.79; 95% CI 0.74–0.83) in predicting DSS was
significantly (p = 0.029) higher than that of the GG (C-index
0.76; 95% CI 0.71–0.82; Fig. 2). The cGrade model (C-index
0.79; 95% CI 0.74–0.84) also showed better discrimination
than the GG model (C-index 0.77; 95% CI 0.72–0.82) for MFS,
although this did not meet conventional measures of
statistical significance (p = 0.062).
3.5. Biochemical recurrence–free survival
Of the 406 patients who had undergone RP, 216 (53%) had
GG1, 129 (32%) GG2, 33 (8%) GG3, 14 (3%) GG4, and 14 (3%)
GG5 Pca. Conversion to the proposed cGrade distribution
resulted in 326 patients (80%) having cGrade1, 34 (8%)
cGrade2, 27 (7%) cGrade3, 12 (3%) cGrade4, and seven (2%)
cGrade5 Pca. In total, 85 (20.9%) patients experienced
biochemical recurrence after a median of 4.5 yr (IQR 2.3–
9.3 yr). Both grading models were strongly associated with
postoperative BCRFS (Table 4). There was no significant
difference (p = 0.4) between the discriminative values of the
cGrade model (C-index 0.65; 95% CI 0.58–0.71) and the GG
model (C-index 0.65; 95% CI 0.59–0.71).
In total, 223 out of 508 patients who received RT (43.9%)
experienced biochemical recurrence after a medianed Prostate Cancer Biopsy Grading by Incorporation of Invasive
. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.07.051
Table 3 – Cox proportional hazard models for prostate cancer disease-specific survival and metastasis-free survival stratified by grade groups
(GGs) and cribriform grade (cGrade).
Disease-specific survival Metastasis-free survival
Group Grade group cGrade Grade group cGrade
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
1 ref – ref – ref – ref –
2 3.1 (1.4–6.6) 0.003 4.6 (2.3–9.1) <0.001 3.8 (1.7–8.4) <0.001 3.7 (1.8–7.7) <0.001
3 10.3 (4.8–22.2) <0.001 8.4 (4.5–15.8) <0.001 10.4 (4.6–23.3) <0.001 9.3 (5.0–17.2) <0.001
4 11.9 (5.3–26.7) <0.001 11.2 (5.9–21.4) <0.001 16.7 (7.3–38.3) <0.001 12.1 (6.4–23.0) <0.001
5 16.4 (7.5–35.8) <0.001 17.9 (9.1–35.2) <0.001 18.0 (7.9–40.9) <0.001 15.6 (7.8–31.2) <0.001
CI = confidence interval; HR = hazard ratio; ref = reference.
Table 4 – Cox proportional hazard models for biochemical recurrence-free survival after radical prostatectomy and radiation therapy
stratified by Grade groups (GG) and cribriform Grade (cGrade).
BCRFS after radical prostatectomy BCRFS after radiation therapy
Group Grade group cGrade Grade group cGrade
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
1 ref – ref – ref – ref –
2 2.1 (1.2–3.5) 0.006 2.2 (1.1–4.4) 0.02 1.9 (1.3–2.8) 0.001 2.5 (1.7–3.7) <0.001
3 4.1 (2.1–7.8) <0.001 4.4 (2.4–7.9) <0.001 4.4 (2.9–6.7) <0.001 4.4 (3.0–6.5) <0.001
4 5.0 (2.2–11.6) <0.001 4.5 (1.9–10.4) 0.001 5.9 (3.8–9.3) <0.001 5.7 (3.8–8.5) <0.001
5 5.2 (2.2–11.9) <0.001 4.4 (1.6–12.2) 0.005 7.5 (4.9–11.5) <0.001 7.4 (4.8–11.5) <0.001
BCRFS = biochemical recurrence–free survival; CI = confidence interval; HR = hazard ratio; ref = reference.
Fig. 2 – Kaplan-Meier survival probabilities of Pca patients graded according to the (A) current grade group model and (B) proposed cGrade model.
cGrade = cribriform grade; GG = grade group; Pca = prostate cancer.
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EURURO-8520; No. of Pages 8follow-up of 4.8 yr (IQR 2.7–8.2 yr). According to the current
grading system, 188 (37%) men had GG1, 154 (30%) GG2, 66
(13%) GG3, 48 (9%) GG4, and 52 (10%) GG5 Pca, correspond-
ing to 306 (60%) cGrade1, 64 (13%) cGrade2, 59 (12%)Please cite this article in press as: van Leenders GJLH, et al. Improve
Cribriform and Intraductal Carcinoma in the 2014 Grade Groups.cGrade3, 44 (9%) cGrade4, and 35 (7%) cGrade5 (Table 4).
The biopsy cGrade (C-index 0.71; 95% CI 0.68–0.75) had a
comparable discriminative value (p = 0.2) for BCRFS after RT
with the GG (C-index 0.72; 95% CI 0.69–0.75).d Prostate Cancer Biopsy Grading by Incorporation of Invasive
 Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.07.051
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The most prominent effect of the cGrade model over the
current GG model is the reclassification of men potentially
being eligible for active surveillance. In total 272/1031
(26.4%) men fulfilled the Prostate Cancer Research Interna-
tional Active Surveillance (PRIAS) criteria for active
surveillance (GG1, positive biopsies 2, cT2, PSA < 10
ng/ml, and PSA density <0.2 ng/ml2). In case cGrade1 was
used instead of GG1, the total number of patients fulfilling
the PRIAS criteria increased by 84 (8.1%) to 356/1031 (34.5%)
of the entire population. The effect was larger if less
stringent eligibility criteria were applied. If the number of
positive biopsies was not taken into account, as increasingly
happens in current practice with larger numbers of
systematic as well as multiparametric magnetic resonance
imaging (mpMRI)-targeted biopsies, the total number of
patients being eligible for active surveillance increased by
151 (14.6%), from 361 (35.0%) for GG1 to 512 (49.7%) for
cGrade1.
4. Discussion
Pathological grading by GS and GG is one of the most
important parameters for predicting Pca outcome and
guiding clinical decision making. In the past decade,
intraductal carcinoma and invasive cribriform carcinoma
have both been recognised as novel pathological features
with independent predictive values for adverse Pca
outcome. Incorporation of these parameters in Pca grading
is, however, needed to facilitate widespread implementa-
tion into clinical practice. In the current study, we
demonstrate that a simple modification of the GG system
with respect to the presence or absence of CR/IDC outper-
forms current Pca grading. In a set of over a thousand
diagnostic prostate biopsies, we found that the cGrade
showed a stronger discriminative value for the prediction of
DSS and MFS than contemporary Pca grading.
In the past decade, the independent predictive value of
additional histopathological features has been recognised.
Intraductal carcinoma is a proliferation of malignant cells in
pre-existent prostate glands, which has been related to an
adverse disease outcome but which is not included in
Gleason grading or the GG [10,11,13,16]. Invasive cribriform
growth is a Gleason pattern 4 subgroup associated with
worse DSS than the other Gleason 4 growth patterns
[5,6,9,17,18]. Invasive cribriform and intraductal carcinoma
show overlapping morphological features, and might be
difficult to differentiate without the use of basal cell
immunohistochemistry. Therefore, both patterns are often
grouped as one entity [13,19]. Percentage Gleason pattern
4 has also been shown to have an additive prognostic value
for Pca outcome [5,15]. However, we did not find any
additive predictive value of Gleason pattern 4. This discor-
dance might be explained by our analysis of percentage
Gleason pattern 4 as a continuous instead of a dichotomised
variable.
One of the most important weaknesses of Gleason grading
is its substantial interobserver variability [20]. While interob-Please cite this article in press as: van Leenders GJLH, et al. Improv
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in patients with GG3–5 Pca, it has significant impact on men
with GG1 and GG2 disease since their distinction commonly
determines eligibility for active surveillance. Grading dis-
cordances particularly occur in differentiating poorly formed
and fused Gleason pattern 4 from tangentially sectioned
pattern 3 [20,21]. Interobserver agreement is, however,
excellent for cribriform pattern 4, which is generally not
confused with Gleason pattern 3 [20,21]. The fact that men
with biopsy GG2 Pca without CR/IDC had comparable clinical
outcome to those with GG1 disease, and the existence of
substantial interobserver variability in distinguishing be-
tween GG1 and GG2 Pca constitute an important rationale for
coalescing both groups into cGrade1 [8,9]. This is also
supported by the low rate of lymph node metastases in
men with GG2 Pca. Diolombi and Epstein [22] found 0.6%
pelvic lymph node metastasis among 3235 men with GG2 Pca
at RP without stratification for CR/IDC. In another GG2 RP
cohort, lymph node metastasis were present in 12/228 (5.3%)
patients with CR/IDC but in none of 192 men without CR/IDC
[23]. Studies comparing the interobserver variability of both
models, however, still have to be performed.
In the current study, 256 out of 310 men with biopsy GG2
disease were reclassified as cGrade1. The proportion of men
fulfilling the PRIAS criteria for active surveillance increased
from 26.4% to 34.5% if cGrade1 was used instead of GG1. This
number further increased if less stringent eligibility criteria
were used. Since upgrading is the most important
parameter for surveillance discontinuation, applying the
cGrade instead of GG would lead not only to a larger number
of patients meeting the inclusion criteria, but also to fewer
dropouts due to grade progression from GG1 to GG2 [24].
Gleason grading has been a work in progress for more
than half a century. The WHO/ISUP significantly modified
the Gleason grading system in 2005 and achieved minor
modifications in 2014 [2,25]. While the cGrade model
outperformed the current GG model, we feel that there is
still room for improvement. For instance, we noted in our
cohort that men with GG4 disease without CR/IDC had DSS
rates comparable to those with GG2 and GG3 disease. This is
in line with the findings of Harding-Jackson et al [27], who
also found relatively good outcome in GG4 Pca patients
without cribriform pattern. With the introduction of the GG
system, all patients with GS8 are classified as GG4 Pca
patients irrespective of the GS being 3 + 5, 4 + 4, or 5 + 3. Van
den Bergh et al found that men with GS 3 + 5 = 8 had
significantly better BCRFS than GS8 patients with any of the
other grade combinations, although such a difference could
not be confirmed by others [26-28]. Detailed analyses for
the presence of CR/IDC in this heterogeneous population of
GG4 Pca patients might further improve Pca grading. At this
moment, we do not advocate to modify Pca grading.
Additional improvements, reproducibility studies, and
independent validations are warranted before grade mod-
ifications can be implemented with broad support of the
scientific community.
The strongest point of this study is the use of a well-
characterised population of Pca patients with long-term
follow-up and strong clinical endpoints. The diagnostic anded Prostate Cancer Biopsy Grading by Incorporation of Invasive
. Eur Urol (2019), https://doi.org/10.1016/j.eururo.2019.07.051
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cantly different from contemporary strategies that include a
larger number of biopsies, application of mpMRI, and active
surveillance. Therefore, validation of the current findings in
more contemporary cohorts is important before its routine
adoption. We expect that the performance of the cGrade
model will be even better in contemporary cohorts, since a
larger number of systematic and targeted biopsies decrease
biopsy sampling artefacts.
5. Conclusions
In this proof-of-principle study, we demonstrate that the
biopsy cGrade is a simple modification of the GG system
having better discriminative values for DSS and MFS than
current Pca grading. Reclassification of GG2 Pca patients
with favourable outcome as cGrade1 might allow more
patients to be considered for active surveillance.
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